Ovarian cancer in the era of immune checkpoint inhibitors: State of the art and future perspectives

Brigida Anna Maiorano, Mauro Francesco Pio Maiorano, Domenica Lorusso, Evaristo Maiello

Research output: Contribution to journalReview articlepeer-review

Abstract

Background: Ovarian cancer (OC) represents the eighth most common cancer and the fifth leading cause of cancer-related deaths among the female population. In an advanced setting, chemotherapy represents the first-choice treatment, despite a high recurrence rate. In the last ten years, immunotherapy based on immune checkpoint inhibitors (ICIs) has profoundly modified the therapeutic scenario of many solid tumors. We sought to summarize the main findings regarding the clinical use of ICIs in OC. Methods: We searched PubMed, Embase, and Cochrane Databases, and conference abstracts from international congresses (such as ASCO, ESMO, SGO) for clinical trials, focusing on ICIs both as monotherapy and as combinations in the advanced OC. Results: 20 studies were identified, of which 16 were phase I or II and 4 phase III trials. These trials used ICIs targeting PD1 (nivolumab, pembrolizumab), PD-L1 (avelumab, aterolizumab, durvalumab), and CTLA4 (ipilimumab, tremelimumab). There was no reported improvement in survival, and some trials were terminated early due to toxicity or lack of response. Combining ICIs with chemotherapy, anti-VEGF therapy, or PARP inhibitors improved response rates and survival in spite of a worse safety profile. Conclusions: The identification of biomarkers with a predictive role for ICIs’ efficacy is mandatory. Moreover, genomic and immune profiling of OC might lead to better treatment options and facilitate the design of tailored trials.

Original languageEnglish
Article number4438
JournalCancers
Volume13
Issue number17
DOIs
Publication statusPublished - Sep 2021

Keywords

  • Avelumab
  • Bevacizumab
  • Checkpoint inhibitors
  • ICIs
  • Immunotherapy
  • Nivolumab
  • Ovarian cancer
  • PARP
  • Pembrolizumab
  • Platinum

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Ovarian cancer in the era of immune checkpoint inhibitors: State of the art and future perspectives'. Together they form a unique fingerprint.

Cite this